113 related articles for article (PubMed ID: 26910074)
1. The Role of MicroRNAs in Resistance to Current Pancreatic Cancer Treatment: Translational Studies and Basic Protocols for Extraction and PCR Analysis.
Garajová I; Le Large TY; Giovannetti E; Kazemier G; Biasco G; Peters GJ
Methods Mol Biol; 2016; 1395():163-87. PubMed ID: 26910074
[TBL] [Abstract][Full Text] [Related]
2. New avenues in pancreatic cancer: exploiting microRNAs as predictive biomarkers and new approaches to target aberrant metabolism.
Capula M; Mantini G; Funel N; Giovannetti E
Expert Rev Clin Pharmacol; 2019 Dec; 12(12):1081-1090. PubMed ID: 31721608
[No Abstract] [Full Text] [Related]
3. Targeting miRNA and using miRNA as potential therapeutic options to bypass resistance in pancreatic ductal adenocarcinoma.
Vahabi M; Dehni B; Antomás I; Giovannetti E; Peters GJ
Cancer Metastasis Rev; 2023 Sep; 42(3):725-740. PubMed ID: 37490255
[TBL] [Abstract][Full Text] [Related]
4. miRNA-21 and miRNA-34a Are Potential Minimally Invasive Biomarkers for the Diagnosis of Pancreatic Ductal Adenocarcinoma.
Alemar B; Izetti P; Gregório C; Macedo GS; Castro MA; Osvaldt AB; Matte U; Ashton-Prolla P
Pancreas; 2016 Jan; 45(1):84-92. PubMed ID: 26262588
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer.
Garajová I; Le Large TY; Frampton AE; Rolfo C; Voortman J; Giovannetti E
Biomed Res Int; 2014; 2014():678401. PubMed ID: 25250326
[TBL] [Abstract][Full Text] [Related]
6. Circulating microRNAs in serum of human K-ras oncogene transgenic rats with pancreatic ductal adenocarcinomas.
Yabushita S; Fukamachi K; Tanaka H; Sumida K; Deguchi Y; Sukata T; Kawamura S; Uwagawa S; Suzui M; Tsuda H
Pancreas; 2012 Oct; 41(7):1013-8. PubMed ID: 22513294
[TBL] [Abstract][Full Text] [Related]
7. MicroRNAs as diagnostic markers for pancreatic ductal adenocarcinoma and its precursor, pancreatic intraepithelial neoplasm.
Xue Y; Abou Tayoun AN; Abo KM; Pipas JM; Gordon SR; Gardner TB; Barth RJ; Suriawinata AA; Tsongalis GJ
Cancer Genet; 2013 Jun; 206(6):217-21. PubMed ID: 23933230
[TBL] [Abstract][Full Text] [Related]
8. State of the art and future directions of pancreatic ductal adenocarcinoma therapy.
Neuzillet C; Tijeras-Raballand A; Bourget P; Cros J; Couvelard A; Sauvanet A; Vullierme MP; Tournigand C; Hammel P
Pharmacol Ther; 2015 Nov; 155():80-104. PubMed ID: 26299994
[TBL] [Abstract][Full Text] [Related]
9. Clinical potential of microRNAs in pancreatic ductal adenocarcinoma.
Steele CW; Oien KA; McKay CJ; Jamieson NB
Pancreas; 2011 Nov; 40(8):1165-71. PubMed ID: 22001830
[TBL] [Abstract][Full Text] [Related]
10. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
11. The microRNA-218 and ROBO-1 signaling axis correlates with the lymphatic metastasis of pancreatic cancer.
He H; Di Y; Liang M; Yang F; Yao L; Hao S; Li J; Jiang Y; Jin C; Fu D
Oncol Rep; 2013 Aug; 30(2):651-8. PubMed ID: 23733161
[TBL] [Abstract][Full Text] [Related]
12. Cell-free plasma microRNA in pancreatic ductal adenocarcinoma and disease controls.
Carlsen AL; Joergensen MT; Knudsen S; de Muckadell OB; Heegaard NH
Pancreas; 2013 Oct; 42(7):1107-13. PubMed ID: 24048453
[TBL] [Abstract][Full Text] [Related]
13. Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma.
Munding JB; Adai AT; Maghnouj A; Urbanik A; Zöllner H; Liffers ST; Chromik AM; Uhl W; Szafranska-Schwarzbach AE; Tannapfel A; Hahn SA
Int J Cancer; 2012 Jul; 131(2):E86-95. PubMed ID: 21953293
[TBL] [Abstract][Full Text] [Related]
14. miR-186 and 326 predict the prognosis of pancreatic ductal adenocarcinoma and affect the proliferation and migration of cancer cells.
Zhang ZL; Bai ZH; Wang XB; Bai L; Miao F; Pei HH
PLoS One; 2015; 10(3):e0118814. PubMed ID: 25742499
[TBL] [Abstract][Full Text] [Related]
15. Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues.
Szafranska AE; Doleshal M; Edmunds HS; Gordon S; Luttges J; Munding JB; Barth RJ; Gutmann EJ; Suriawinata AA; Marc Pipas J; Tannapfel A; Korc M; Hahn SA; Labourier E; Tsongalis GJ
Clin Chem; 2008 Oct; 54(10):1716-24. PubMed ID: 18719196
[TBL] [Abstract][Full Text] [Related]
16. Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas.
Mees ST; Mardin WA; Sielker S; Willscher E; Senninger N; Schleicher C; Colombo-Benkmann M; Haier J
Ann Surg Oncol; 2009 Aug; 16(8):2339-50. PubMed ID: 19475450
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of miR-194 contributes to tumor growth and progression in pancreatic ductal adenocarcinoma.
Zhang J; Zhao CY; Zhang SH; Yu DH; Chen Y; Liu QH; Shi M; Ni CR; Zhu MH
Oncol Rep; 2014 Mar; 31(3):1157-64. PubMed ID: 24398877
[TBL] [Abstract][Full Text] [Related]
18. Enhancer of zeste homolog 2 silences microRNA-218 in human pancreatic ductal adenocarcinoma cells by inducing formation of heterochromatin.
Li CH; To KF; Tong JH; Xiao Z; Xia T; Lai PB; Chow SC; Zhu YX; Chan SL; Marquez VE; Chen Y
Gastroenterology; 2013 May; 144(5):1086-1097.e9. PubMed ID: 23395645
[TBL] [Abstract][Full Text] [Related]
19. MicroRNAs: novel diagnostic and therapeutic tools for pancreatic ductal adenocarcinoma?
Mardin WA; Mees ST
Ann Surg Oncol; 2009 Nov; 16(11):3183-9. PubMed ID: 19636633
[TBL] [Abstract][Full Text] [Related]
20. Molecular alterations contributing to pancreatic cancer chemoresistance.
Rajabpour A; Rajaei F; Teimoori-Toolabi L
Pancreatology; 2017; 17(2):310-320. PubMed ID: 28065383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
